Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Australian dollar dips, traders cautiously welcome vaccine news

Published 10/11/2020, 02:33 pm
Updated 10/11/2020, 02:36 pm
© Reuters.

By Paulina Duran

SYDNEY, Nov 10 (Reuters) - The Australian dollar traded slightly lower against its U.S. counterpart on Tuesday while the New Zealand dollar was marginally higher, as traders weighed news about progress in the development of a coronavirus vaccine.

The Aussie was trading 0.03% lower at $0.7277 AUD=D3 on Tuesday Sydney time, having hit its highest level in two months in late intraday trading on Monday at $0.7340 after Pfizer Inc (NYSE:PFE) PFE.N said its experimental vaccine was more than 90% effective in preventing COVID-19.

The currency later lost some of its gains to close flat on Monday.

Pfizer's vaccine is more than 90% effective based on initial trial results, the drugmaker said on Monday. But even if it gets regulatory approvals, mass rollouts will not happen this year. the market did overreact to the vaccine, given there's still some way to go prove that it's safe," said Westpac currency analyst Imre Speizer.

"What they've shown is that it's reasonably effective, safety is another stage. Once the market looked into the finer print of what these results were, maybe they backed off the trade a bit."

The New Zealand dollar was 0.18% higher to $0.6830 NZD=D3 on Tuesday, which was also lower than the intraday high of $0.6854 on Monday when traders reacted to Joe Biden's clinching of the U.S. presidency over the weekend and the vaccine news.

The antipodean currencies had weakened in recent weeks as their central banks signalled further monetary policy easing to rescue their economies from the coronavirus crisis.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The Reserve Bank of Australia (RBA) this month cut and vowed to maintain its cash rate at 0.10% and shifted to quantitative easing (QE), while its counterpart in New Zealand is expected to announce a cheap funding facility for banks on Wednesday and cut rates below zero next year.

Australian yields had been falling after the RBA's bond-buying announcement, but bonds were now tracking the direction of U.S. rates, which were sold off following Pfizer's findings.

On Tuesday, ten-year Australian bond yields AU10YT=RR were 13 basis points higher at 0.91%, while three-year bonds AU3YT=RR were half a tick higher at 0.11%.

The mirroring dynamic was likely to continue while the trajectory of yields in the near term was uncertain, analysts said.

Control of the U.S. Senate won't be known until January, and rolling out an effective vaccine to enough people is unlikely to be quick enough to prevent further restrictions on activity and movements.

"It seems likely that more stimulus – monetary and fiscal – is likely to come. With COVID-19 cases reaching new highs in the U.S., it is hard to see the services sector growing strongly in the near term," Australia and New Zealand Banking Group strategists said.

" But the combination of a slowing recovery and possible lacklustre fiscal support will likely lead to the Fed providing more stimulus, most likely through more bond purchases. This should cap the upside in yields." (Editing by Uttaresh.V)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.